Beauty Is A Pain: FDA Cites Latisse Web Site For Implying Drug Is A Cosmetic
Executive Summary
Allergan's consumer Web site for its eyelash growth drug, Latisse,certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic
You may also be interested in...
Fibrocell's Wrinkle Drug Underlines Challenges Of Seeking Aesthetic Claims
An FDA advisory committee made very clear that the bar should be much higher for novel products proposed for aesthetic indications than for drugs to treat diseases during the Oct. 9 review of Fibrocell Science's wrinkle therapy Laviv (azfibrocel-T)
Fibrocell's Wrinkle Drug Underlines Challenges Of Seeking Aesthetic Claims
An FDA advisory committee made very clear that the bar should be much higher for novel products proposed for aesthetic indications than for drugs to treat diseases during the Oct. 9 review of Fibrocell Science's wrinkle therapy Laviv (azfibrocel-T)
Allergan Under Investigation By Oregon For Deceptive Promotions
State effort is focused on one unnamed drug but may expand; the company is already facing a federal inquiry about off-label promotion of Botox for headache treatment.